Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein-arginine N-methyltransferase 4 (PRMT4), also known as CARM1, is an epigenetic enzyme that catalyzes the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to arginine residues in proteins, resulting in asymmetric dimethylation. This post-translational modification regulates gene transcription, RNA splicing, cell proliferation, and development. PRMT4 methylates histone H3 at arginines 17 and 26, and non-histone proteins, influencing chromatin structure and gene expression. It is implicated in cancer and immune suppression during sepsis. Inhibitors like TP-064 have been developed for research. Knockout studies show PRMT4 is essential for mouse development.
Inhibition of PRMT4 enzymatic activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein-arginine N-methyltransferase 4 (CARM1).